Radium-223 and concomitant therapies: prospects and prudence.

about

Current perspectives on bone metastases in castrate-resistant prostate cancer.Multifaceted Roles for Macrophages in Prostate Cancer Skeletal Metastasis.

P2860

Q49285273-7A579098-3CC4-4837-B177-B1D8499F0549 Q55364968-977DDD8E-E263-4991-954A-5B2A04D41429

P2860

Radium-223 and concomitant therapies: prospects and prudence.

Item

http://www.wikidata.org/entity/Q42343422

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Radium-223 and concomitant therapies: prospects and prudence.

@en

Radium-223 and concomitant therapies: prospects and prudence.

@nl

type

Item

label

Radium-223 and concomitant therapies: prospects and prudence.

@en

Radium-223 and concomitant therapies: prospects and prudence.

@nl

prefLabel

Radium-223 and concomitant therapies: prospects and prudence.

@en

Radium-223 and concomitant therapies: prospects and prudence.

@nl

P1476

Radium-223 and concomitant therapies: prospects and prudence.

@en

P2093

Oladapo Yeku

http://www.w3.org/2001/XMLSchema#string

Susan F Slovin

http://www.w3.org/2001/XMLSchema#string

P2860

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

Roles of bone marrow cells in skeletal metastases: no longer bystanders

Mechanisms of cancer cell metastasis to the bone: a multistep process.

A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy.

Bone metastasis and the metastatic niche.

P304

968-970

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/TAU.2016.11.04

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28078234

http://www.w3.org/2001/XMLSchema#string

P932

5182218

http://www.w3.org/2001/XMLSchema#string

Radium-223 and concomitant therapies: prospects and prudence.

about

P2860

P2860

Radium-223 and concomitant therapies: prospects and prudence.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932